Protalix BioTherapeutics Inc (PLX)
1.21
+0.01
(+0.83%)
USD |
NYAM |
Apr 24, 16:00
1.215
0.00 (0.00%)
After-Hours: 20:00
Protalix BioTherapeutics Revenue (Quarterly): 10.49M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.49M |
| September 30, 2023 | 10.34M |
| June 30, 2023 | 35.08M |
| March 31, 2023 | 9.588M |
| December 31, 2022 | 8.617M |
| September 30, 2022 | 14.18M |
| June 30, 2022 | 8.753M |
| March 31, 2022 | 16.08M |
| December 31, 2021 | 8.549M |
| September 30, 2021 | 12.05M |
| June 30, 2021 | 6.427M |
| March 31, 2021 | 11.32M |
| December 31, 2020 | 19.50M |
| September 30, 2020 | 10.79M |
| June 30, 2020 | 10.97M |
| March 31, 2020 | 21.65M |
| December 31, 2019 | 17.76M |
| September 30, 2019 | 14.25M |
| June 30, 2019 | 12.25M |
| March 31, 2019 | 10.44M |
| December 31, 2018 | 10.35M |
| September 30, 2018 | 12.34M |
| June 30, 2018 | 4.838M |
| March 31, 2018 | 6.714M |
| December 31, 2017 | 4.305M |
| Date | Value |
|---|---|
| September 30, 2017 | 7.526M |
| June 30, 2017 | 6.358M |
| March 31, 2017 | 2.889M |
| December 31, 2016 | 2.081M |
| September 30, 2016 | 4.67M |
| June 30, 2016 | 1.769M |
| March 31, 2016 | 0.679M |
| December 31, 2015 | |
| September 30, 2015 | 1.336M |
| June 30, 2015 | 1.336M |
| March 31, 2015 | 1.692M |
| December 31, 2014 | -10.25M |
| September 30, 2014 | 3.707M |
| June 30, 2014 | 2.686M |
| March 31, 2014 | 7.383M |
| December 31, 2013 | -10.39M |
| September 30, 2013 | 3.359M |
| June 30, 2013 | 3.064M |
| March 31, 2013 | 3.968M |
| December 31, 2012 | 0.048M |
| September 30, 2012 | 5.39M |
| June 30, 2012 | 25.26M |
| March 31, 2012 | 3.728M |
| December 31, 2011 | 0.689M |
| September 30, 2011 | 0.897M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
6.427M
Minimum
Jun 2021
35.08M
Maximum
Jun 2023
13.61M
Average
11.32M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
| Agenus Inc | 83.80M |
| InfuSystems Holdings Inc | 31.77M |
| Corbus Pharmaceuticals Holdings Inc | -- |
| AIM ImmunoTech Inc | 0.065M |
| Armata Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.044M |
| Total Expenses (Quarterly) | 16.10M |
| EPS Diluted (Quarterly) | -0.10 |
| Enterprise Value | 64.08M |
| Gross Profit Margin (Quarterly) | 15.54% |
| Profit Margin (Quarterly) | -57.64% |
| Earnings Yield | 1.65% |
| Operating Earnings Yield | 11.12% |
| Normalized Earnings Yield | 1.653 |